These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. Hu JL; Omofoye OA; Rudnick JD; Kim S; Tighiouart M; Phuphanich S; Wang H; Mazer M; Ganaway T; Chu RM; Patil CG; Black KL; Shiao SL; Wang R; Yu JS Clin Cancer Res; 2022 Feb; 28(4):689-696. PubMed ID: 34862245 [TBL] [Abstract][Full Text] [Related]
27. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363 [TBL] [Abstract][Full Text] [Related]
28. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Vik-Mo EO; Nyakas M; Mikkelsen BV; Moe MC; Due-Tønnesen P; Suso EM; Sæbøe-Larssen S; Sandberg C; Brinchmann JE; Helseth E; Rasmussen AM; Lote K; Aamdal S; Gaudernack G; Kvalheim G; Langmoen IA Cancer Immunol Immunother; 2013 Sep; 62(9):1499-509. PubMed ID: 23817721 [TBL] [Abstract][Full Text] [Related]
30. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866 [TBL] [Abstract][Full Text] [Related]
31. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms of immunomodulation in human glioblastoma. Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170 [TBL] [Abstract][Full Text] [Related]
33. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472 [TBL] [Abstract][Full Text] [Related]
34. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743 [TBL] [Abstract][Full Text] [Related]
35. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459 [TBL] [Abstract][Full Text] [Related]
36. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813 [TBL] [Abstract][Full Text] [Related]
37. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients. Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145 [TBL] [Abstract][Full Text] [Related]
38. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Rampling R; Peoples S; Mulholland PJ; James A; Al-Salihi O; Twelves CJ; McBain C; Jefferies S; Jackson A; Stewart W; Lindner J; Kutscher S; Hilf N; McGuigan L; Peters J; Hill K; Schoor O; Singh-Jasuja H; Halford SE; Ritchie JW Clin Cancer Res; 2016 Oct; 22(19):4776-4785. PubMed ID: 27225692 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials. Lv L; Huang J; Xi H; Zhou X Int Immunopharmacol; 2020 Jun; 83():106336. PubMed ID: 32213460 [TBL] [Abstract][Full Text] [Related]
40. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]